Jubi-R (Remdesivir) 100 mg
Jubi-R (Remdesivir 100 mg) is an antiviral medication that targets the SARS-CoV-2 virus directly.
Manufacturer: Jubilant Generics. This is an Authorized Generic manufactured under a direct license from Gilead Sciences (USA), ensuring the same quality and efficacy as the originator brand (Veklury).
Mechanism of Action ("RNA Sabotage"):
Remdesivir acts as a nucleotide analog. It inserts itself into the viral RNA chains, causing a premature termination of viral replication. Essentially, it stops the virus from making copies of itself inside your body.
โ Key Benefit: Reduces recovery time and prevents disease progression in patients requiring oxygen support.
Indicated for the treatment of COVID-19 in adults and adolescents.
Usage Guidelines:
- ๐ฅ Hospital Setting: For patients with pneumonia requiring supplemental oxygen.
- โฐ Timing is Key: Clinical data suggests highest efficacy when administered early (within the first 5-10 days of symptom onset) during the viral replication phase.
Form: Lyophilized powder for Injection (IV Infusion only).
โ ๏ธ PROFESSIONAL ADMINISTRATION REQUIRED:
Standard Regimen:
- Day 1 (Loading Dose): 200 mg (2 vials) infused intravenously.
- Days 2โ5 (Maintenance Dose): 100 mg (1 vial) once daily.
๐ Note: Must be reconstituted with sterile water and further diluted in 0.9% Saline solution before administration.
- Severe renal impairment (eGFR < 30 mL/min).
- Severe hepatic impairment (ALT > 5 times the upper limit of normal).
- Hypersensitivity to Remdesivir.
Monitoring is required during treatment:
- Liver Function: Elevated transaminase levels (ALT/AST). Daily blood tests are recommended.
- Infusion-related reactions: Nausea, hypotension, sweating, or shivering during administration.
- Allergic reactions (rare).
What Customers Say
No reviews yet
Your review can be the first!